Skip to main content

Inovio Pharmaceuticals (INO) Receives a Buy from Piper Sandler

Tipranks - Tipranks - Sat Nov 15, 2025

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $6.00.

Meet Your ETF AI Analyst

According to TipRanks, Tenthoff is an analyst with an average return of -7.7% and a 36.83% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Alnylam Pharma, and Skye Bioscience.

In addition to Piper Sandler, Inovio Pharmaceuticals also received a Buy from Oppenheimer’s Hartaj Singh in a report issued on November 11. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Inovio Pharmaceuticals (NASDAQ: INO).

See today’s best-performing stocks on TipRanks >>

Based on Inovio Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $45.5 million. In comparison, last year the company had a GAAP net loss of $25.17 million

Read More on INO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).